A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
Clinical trial NCT04304040 · UNKNOWN
Trial details
- NCT number
- NCT04304040
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-28
- Primary completion
- 2025-12-30
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.